ZA200609458B - Herbal composition - Google Patents
Herbal composition Download PDFInfo
- Publication number
- ZA200609458B ZA200609458B ZA200609458A ZA200609458A ZA200609458B ZA 200609458 B ZA200609458 B ZA 200609458B ZA 200609458 A ZA200609458 A ZA 200609458A ZA 200609458 A ZA200609458 A ZA 200609458A ZA 200609458 B ZA200609458 B ZA 200609458B
- Authority
- ZA
- South Africa
- Prior art keywords
- herbal composition
- herbal
- extract
- composition according
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 117
- 239000000284 extract Substances 0.000 claims description 68
- 208000024891 symptom Diseases 0.000 claims description 31
- 208000036142 Viral infection Diseases 0.000 claims description 25
- 230000009385 viral infection Effects 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 19
- 208000025865 Ulcer Diseases 0.000 claims description 18
- 231100000397 ulcer Toxicity 0.000 claims description 18
- 208000010201 Exanthema Diseases 0.000 claims description 17
- 208000004898 Herpes Labialis Diseases 0.000 claims description 17
- 206010067152 Oral herpes Diseases 0.000 claims description 17
- 206010000496 acne Diseases 0.000 claims description 17
- 201000005884 exanthem Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 206010037844 rash Diseases 0.000 claims description 17
- 206010040882 skin lesion Diseases 0.000 claims description 17
- 231100000444 skin lesion Toxicity 0.000 claims description 17
- 239000012674 herbal formulation Substances 0.000 claims description 14
- 241000701022 Cytomegalovirus Species 0.000 claims description 12
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 12
- 241000701806 Human papillomavirus Species 0.000 claims description 12
- 241000700584 Simplexvirus Species 0.000 claims description 12
- 239000000969 carrier Substances 0.000 claims description 10
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 9
- 235000003880 Calendula Nutrition 0.000 claims description 9
- 240000001432 Calendula officinalis Species 0.000 claims description 9
- 241000546188 Hypericum Species 0.000 claims description 8
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 8
- 241000218636 Thuja Species 0.000 claims description 8
- 241000202726 Bupleurum Species 0.000 claims description 7
- 240000003553 Leptospermum scoparium Species 0.000 claims description 7
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 241001106041 Lycium Species 0.000 claims description 6
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 6
- 240000002657 Thymus vulgaris Species 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 229940069445 licorice extract Drugs 0.000 claims description 6
- 239000001585 thymus vulgaris Substances 0.000 claims description 6
- 229940098465 tincture Drugs 0.000 claims description 6
- 235000003130 Arctium lappa Nutrition 0.000 claims description 5
- 235000008078 Arctium minus Nutrition 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 240000007643 Phytolacca americana Species 0.000 claims description 5
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 5
- 241000405414 Rehmannia Species 0.000 claims description 5
- 240000006079 Schisandra chinensis Species 0.000 claims description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 5
- 235000020694 echinacea extract Nutrition 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 235000021419 vinegar Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 240000000724 Berberis vulgaris Species 0.000 claims description 4
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 4
- 235000014138 Caesalpinia decapetala Nutrition 0.000 claims description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 4
- 244000272459 Silybum marianum Species 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims description 4
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 4
- 235000011472 cat’s claw Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000008397 ginger Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 235000010841 Silybum marianum Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 244000133098 Echinacea angustifolia Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 235000014134 echinacea Nutrition 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 244000294263 Arctium minus Species 0.000 claims 3
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 3
- 241000532353 Porzana Species 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 description 30
- 208000000260 Warts Diseases 0.000 description 29
- 238000011282 treatment Methods 0.000 description 28
- 241000700605 Viruses Species 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000700586 Herpesviridae Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 240000005528 Arctium lappa Species 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- -1 transdermal patches Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 241001516739 Platonia insignis Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000015728 Taxus canadensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940045811 echinacea purpurea extract Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
. HERBAL COMPOSITION
The invention relates to a herbal composition.
Specifically, the invention ralates to a herbal 5S composition suitable for alleviating, treating and/or preventing symptoms associated with or caused by viral infections.
The use of plants and plant extracts in the treatment of disease and illness has occurred for centuries. Many of the medicines that are used today originate from early herbal remedies and formulations. For example, morphine and codeine are derived from opium poppies, while taxol, which is used in the treatment of breast cancer, is derived originally from the Pacific Yew tree.
Vviruges are super molecular complexes of nucleic acids, either DNA or RNA, encapsulated in a protein coat.
Viruses may infect animal cells and plant cells. Once a virus gains access to the specific host cell, it can alter or manipulate the function of the host cell producing undesirable side effects.
Viruses of the Herpesviridae family of viruses such as Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV) and Cytomegalo Virus (CMV) are amongst the most common viruses affecting adults and children. Another common family of viruses is the Papovaviridae family of viruses, which includes the Human Papilloma Virus (HPV).
Coxsackie B virus is also a common virus, most prominently affecting children.
Herpes viruses (Herpesviridae) are another class of virus common in the general population and include
Herpes Simplex Virus (HSV), which causes irritable skin lesions, Epstein-Barr Virus (EBV), which causes infectious mononucleosis, and Cytomegalo Virus (CMV), which causes cytomegalo virus inclusion dissass.
Ss
There are two different strains of HSV. Herpes simplex virus type 1 (HSV-1) is usually associated with infections of the lips, mouth, and face. It is the most common herpes simplex virus among the general population and is usually acquired in childhood. H3V-1 often causes lesions inside the mouth such as cold sores. Herpes simplex virus 2 (HSV-2) is gexually transmitted and is usually associated with genital ulcers or sores.
EBV is most present in adolescent populations in developed countries. Transmission appears to be exposure to EPV-contaminated saliva. The virus undergoes a replicated cycle in the oropharyngeal epithelium and then invades the blood by infecting B cells. The infection manifests itself by fever, sore throat, and the appearance in the blood of atypical lymphocytes. For EBV, the treatments include bed rest and taking analgesic (aspirin) to relieve the fever and headaches.
CMV is primarily a sexually transmitted disease and manifests itself in mononucleosis-like symptoms, which include fever and body aches. In some cases, the virus may be without symptoms at all. People with HIV seem to be preferentially infected via the eye in the form of CMV retinitis.
Many different types of Human Papilloma Virus (HPV) cause warts, which are a common epithelial tumor.
HPV infects skin cells epithelial keratinocytes. The viruses replicate in skin cells, causing a variety of external growths. The usual mode of transmission of the virus is by skin to skin inoculation, although it is not well understood how the virus penetrates and infects cells. .
There is often a wide variation in time between infection and manifestation of visible warts: with common warts from several daye to several weeks. Genital warts may not appear until more than a year after infection. It is believed that some resistance to the manifestation may be due to cell mediating immune responses.
Current treatments for symptoms of HPV, such as warts, include burning or freezing the infected area of gkin. In some instances the infected area may be surgically removed. All these treatments can be painful and may not prevent warts from returning. Generally the ] current treatment can broadly be defined as topical and symptomatic.
The current orthodox methods for treating symptoms of viral infections are few and of limited benefit. Therefore, there is a need to provide an improved treatment for symptoms of viral infections or to at least provide the public with a useful, alternative choice of treatment.
According to a first aspect of the invention, there is provided a herbal composition comprising extracts from:
Thuja;
Bupleurum;
Echinacea;
Calendula;
Licorice; and
Hypericum.
The herbal composition may further comprise extracts of one or more of Manuka, Lycium, Burdock, Cats
Claw, Poke root, Ginger, Thyme, Barberry, Golden Seal and
Rehmannia, Schisandra, and St Mary's Thistle.
A second aspect of the invention provides a mathod of alleviating, treating and/or preventing symptoms of skin lesions, sores, cold sores, blisters, warte, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection which comprises administering a therapeutically effective amount of the herbal composition as defined above to a subject in need thereof.
A third aspect of the invention provides use of the herbal composition as defined above for the manufacture of a medicament to alleviate, treat and/or prevent symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
A fourth aspect of the invention provides use of the herbal composition as defined above to alleviate, treat and/or prevent symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
A fifth aspect of the invention provides the herbal composition as defined above for use in alleviating, treating and/or preventing symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
A sixth aspect of the invention provides an agent comprising the herbal composition as defined above for alleviating, treating and/or preventing symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection. 5
The viral infections include, but are not limited to, the Herpesviridae family of viruses such as Herpes
Simplex Virus (HSV), Epstein-Barr virus (EBV) and
Cytomegalo Virus (CMV); the Papovaviridae family of viruses such as Human Papilloma Virus (HPV); and the
Coxsackie B virus.
The herbal composition may conveniently be administered together with one or more carriers. Thus a seventh aspect of the invention provides the herbal composition as defined above together with one or more carriers.
The herbal composition is suitably administered orally and/or topically.
In the subject specification, except where the context requires otherwise due to express language or necessary implication, the words “comprise” or variations such as “comprises” or “comprising” are used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
It must be noted that, as used in the subject specification, the singular forms “a”, “an” and “the” include plural aspects unless the context clearly dictates otherwise. Thus, for example, reference to “an extract” includes a single extract, as well as two or more extract;
and so forth.
The term “extract” as used herein should be taken in the broadest possible senses. “Extracts” may include tinctures, fluid extracts or solid extracts, for example.
In a preferred form of the invention, the extracts are tinctures. Tinctures may be formed from water-based infusions and decoctions. Alternative bases for the extract may include acetracts {to form a vinegar extract), glycetracts (to form a glycerine extract), mels (to form a honey extract), oxymels (honey and vinegar), or syrups (to form a sugar extract).
Tinctures are prepared by methods well known in the art. Briefly, however, a fresh plant tincture is made by first obtaining a herb dried by air as known in the art. The dried herbs are then further dried in an oven at a temperature of between 60°C and 70°C. The oven dried herbs are then suspended in a solution in a storage container. In a preferred form, the golution is a mixture of alcohol and water. To make up a 1:5 tincture, 75 gms of oven dried herb is suspended in 375 ml of the solution (weight of herb x 5 to get 1:5 ratio) in a storage container. The storage container is allowed to stand for about 6 weeks and is shaken periodically. The mixture is then filtered and the solution withdrawn provides the tincture used.
Other methods of extracting herbs are well known in the field. For example, cold percolation techniques may be used to prepare tinctures.
The tinctures may also be purchased from herbal puppliers such as MediHerb Pty Ltd, 124 McEvoy B8treet,
Warwick, Queensland 4370, Australia in a ready-to-use formulation.
The extracts may be prepared from any part of the herb plant such as, for example, foliage, leaves, the root, flowers, bark, stems or rhizome, seads, and fruit.
Howevar, particular parts of the herb plant are usually used to prepara the extracts.
A Thuja extract is usually made from the foliage.
The herbal composition preferably comprises from about 0.9% to about 55% of Thuja extract, and more preferably about 18% of Thuja extract.
A Bupleurum extract is usually made from the root. The herbal composition preferably comprises from about 0.9% to about 72% of Bupleurum extract, and more preferably about 18% of Bupleurum extract.
An Echinacea extract is usually made from the root or the whole plant of the herb. The herbal composition preferably comprises from about 0.9% to about 55% of Echinacea extract, and more preferably about 23% of
Echinacea extract.
A Calendula extract is usually made from the flowers. The herbal composition preferably comprises from about 0.9% to about 36% of Calendula extract, and more preferably about 9% of Calendula extract.
A Licorice extract is usually made from the root.
The herbal composition preferably comprises from about 0.9% to about 36% of Licorice extract, and more preferably about 14% of Licorice extract.
A Hypericum extract is usually made from the flowers. The herbal composition preferably comprises from about 1.5% to about 55% of Hypericum extract, and more preferably about 18% of Hypericum extract.
The herbal composition may include one or more different kinds of extracts. For example, the different herbe may be processed to form extracts by different means. Similarly, the herbal composition may comprise a mixture of two or more types of extracts of a particular herb.
Table 1 illustrates a herbal composition of a preferred embodiment of the invention.
Table 1 (mje |muja cccidemcalie [ose lus [10m [schinaces | mchimsces purpures [Boot [1a |0-som
In addition to the above-mentioned herb extracts, the herbal composition may further comprise one or more additional herb extracts, which may also assist in alleviating, treating and/or preventing symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by viral infections. Examples include herb extracts having anti-viral properties such as Manuka, Thyme and Barberry, or properties that stimulate the immune system such as
Lycium, Burdock, Cats Claw, Poke root, Ginger, Golden
Seal, Rehmannia, Schisandra, and 8t Mary’s Thistle.
Manuka (i.e. Leptospermum scoparium) extract is usually made the lsaves of the plant.
A Lycium (i.e. Lycium barbarum) extract is
1°} usually made from the fruit.
A Burdock (i.e. Arctium lappa) extract is usually made from the root.
A Cats Claw (i.e. Uncaria tormentosa) extract is usually made from inner bark of the vine.
A Poke root (i.e. Phytolacca decandra) extract is usually made from the root.
A Ginger (i.e. Zingerber officinale) extract is usually made from the root or rhizome.
A Thyme (i.e. Thymus spp) is usually made from the leaves of the plant.
A Barberry (i.e. Berberis vulgaris) extract is usually made from the inner bark of the plant.
A Golden Seal (i.e. Hydrastis canadensis) extract is usually made from the root or rhizome.
A Rehmannia (i.e. Rehmannia glutinosa) extract is usually made from the root.
A Schisandra (i.e. Schisandra chinensis) extract is usually made from the fruit.
A St Mary’s Thistle (e.g. Silybum marianum) extract is usually made from the seed.
The herbal composition may comprise from about 0.1% to about 30%, more preferably from about 0.1% to about 10%, of each of the above-mentioned additional herb extracts.
The viral infections include, but are not limited to, the Herpesviridae family of viruses such as Herpes
Simplex Virus (HSV), Epstein-Barr Virus (EBV) and
Cytomegalo Virus (CMV); the Papovaviridae family of viruses such as Human Papilloma Virus (HPV); and the
Coxsackie B virus.
Not wishing to be bound by a particular theory or hypothesis the inventor believes that the surprising and unexpected effects seen with the herbal composition results from synergism between the individual components.
The term “subject” as used herein refers to any animal having symptoms associated with or caused by viral infections, which requires treatment with the herbal composition. The subject may be an animal, such as a mammal, preferably a human, or may be a non-human primate or non-primates such as used in animal model testing.
While it is particularly contemplated that the herbal composition is suitable for use in medical treatment of humans, it is also applicable to veterinary treatment, including treatment of companion animals such as dogs and cats, and domestic animals such as horses, ponies, donkeys, mules, llama, alpaca, pigs, cattle and sheep, or zoo animals such as primates, felids, canids, bovids, and ungulates.
Generally, the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing one or more symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection, and/or may be therapeutic in terms of a partial or complete cure of one or more symptoms of skin lesions, sores, cold sores,
blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection. “Treating” as used herein covers any alleviation, treatment, ox prevention of one or more symptom2 of egkin lesions, sores,
S cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or causad by 2 viral infection in an animal such as a mammal, more particularly a human, and includes: (a) preventing ome or more of the symptoms referred to above from occurring in a subject that may be predisposed to such symptoms, but has not yet been diagnosed as having the viral infection; (b) inhibiting one or more of the symptoms referred to above, i.e. arresting development of one or more of the symptoms referred to above; or (c) alleviating, relieving or ameliorating the effects, i.e. cause regression, of one or more of the symptoms referred to above.
As used herein, the term “effective amount” means an amount of the herbal composition to alleviate, treat and/or prevent symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection in order to yield a desired therapeutic response. For example, to overcome or alleviate the effects of one or more of those symptoms.
The term “therapeutically effective amount” means an amount of the herbal composition to yield a desired therapeutic response. For example, alleviating, treating and/or preventing the symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection. 35 .
The herbal composition may conveniently be administered together with one or more carriers. Carriers include substances that are useful in preparing a formulation comprising the herbal composition, may be in co-administration with the composition while allowing the individual components to perform their intended function, and are generally safe, non-toxic and are neither biologically or otherwise undesirsbls. In addition, carriers will include those suitable for veterinarian use as well as human use. Examples of carriers include dispersing agente, suspending agents, emulsifying agents, stabilising agents, wetting agents, binding agents, lubricants, disintegrants, solvents, media, delay agents, fillers, aqueous and oily bases, non-aqueous vehicles, i.e. edible oils, and the like.
In addition, the herbal composition may contain preserving agents, sweetening agents, colouring agents, flavouring agents, thickening and/or gelling agents, buffers and the like. Those skilled in the art will be able to identify further additives that may be desirable for cosmetic reasons, palatability, or shelf life, for example.
As it will be appreciated by those skilled in the art to which the invention relates, the herbal composition may be converted into customary formulations. Examples of formulations include, but are not limited to, solutions, emulsions, suspensions, powders, granules, natural and synthetic materials impregnated with the individual components of the herbal composition, pills, capsules, tablets, cachets, pastilles, lozenges, bolus, electuary, pastes, ointments, creams, plasters, washes, lotions, transdermal patches, enemas, suppositories, pessaries, sprays (atomiser, or aerosol) mouthwashes, syrups, and/or elixirs. Preferably, the formulation is in the form of a solution or a cream. The inventor notes that in the case of warts (HPV infection) such formulations (i.e. oral solutions and topical creams) are particularly useful.
The choice of carriers and/or additives may be dictated to some extent by the intended dosage form of the herbal composition and the mode of administration of the herbal composition.
Formulations comprising the herbal composition may be produced by a number of techniques standard in the art, for example, by mixing the herbal extracts with one or more carriers and/or additives.
Formulations suitable for oral administration may conveniently be presented in discrete units such as capsules, cachets or tablets each containing a predetermined amount of the herbal composition; as a powder or granules; as a solution, a suspension or as an emilgion. The herbal composition may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional carriers such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may for example be in the form of aqueous or oily suspensions, emulsions, syrups or elixirs, or may be presented as a dry product, such as a powder or granules, for constitution with water or another suitable vehicle, e.g. orange juice, before use. Suitable carriers for such liquid preparations may include, for example, ethyl alcohol, vinegars, glycerine, honey, sugar, or water. Such liquid preparations may also contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles, which may include edible oils, or preservatives.
For topical administration to the skin, the herbal composition may be formulated as ointments, creams, plasters, washes, lotions, or as a transdermal patch.
Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. The Calendula present in the herbal composition may also be in the form of an oil infused with Calendula flower. Additionally, an essential oil of Thyme may be present. Lotions and washes may be formulated with an aqueous or oily base, and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspanding agents, thickening agents, or colouring agents.
Formulations suitable for topical administration in the mouth include lozenges comprising the herbal composition and may have a flavoured base such as sucrose and gum acacia or gum tragacanth; pastilles comprising the herbal composition in an inert base such as gelatin or sucrose and gam acacia; and mouthwash in a suitable liquid carrier.
In use, the herbal composition would be administered to a subject as needed, as desired, or as advised by a medical practitioner, pharmacist, attendant physician, medical herbalist, naturopath, or veterinarian.
The selection of the herb extracts may also be made on the sgpeclfic needs of the subject.
As will be appreciated, the dose administered, the period of administration, and the general administration regime may differ between subjects depending on variables such as their tolerance to certain active ingredients, weight, metabolism, the mode of administration chosen, the severity of the symptoms, and the age and/or general health of the subject. In general, however, a suitable dose of an oral formulation is preferably in the range of from about lml to about 50ml, at least once daily, more preferably from about éml to about 10ml, at least twice daily, most preferably about 8 ml at least twice daily. Oral treatment may also be supplemented with a topical application.
Treatment is preferably commenced befors or at the time symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection develop and preferably continues until such symptoms are no longer present.
The invention will now be further elucidated by reference to the following non-limiting example.
EXAMPLE 1
Study Design
The study was designed for 40 participants.
Participants in the atudy were selected from the public.
Respondents with any pre-existing health condition that may have been adversely affected by the herbal composition were excluded from the trial. These conditions included elevated blood pressure, kidney insufficiency, pregnancy, lactation, and epilepsy.
The respondents had a wide range of “skin lumps” that they called warts, including a range of keratoses and some basal cell carcinomas.
After screening the prospective participants, 40 participants were chosen who met the following criteria: © ages of 18 to 70, ° having benign warts verified by a medical le practitioner; and ) no serious pre-existing medical condition.
Each of the 40 participanteg received an individual consultation, with the principal researcher taking comprehensive medical history notes, including the history of their warts and any previous treatments for them. Participants had their blood pressure measured and also completed a medical history form.
Participants had their warts photographed, identified by their code number placed next to each wart.
The scale was determined by placing a ruler in the photograph.
Control group
Of the 40 participants, 20 participants were randomly selected to form the control group.
The control group had no treatment and at the end of the l1l2-week trial period, each participant in this group had their warts re-photographed.
Treatment group
The treatment group, which consisted of the remaining 20 participants, took a herbal composition : prepared as an oral formulation comprising: 20 ml of Thuja extract; 20 ml of Bupleurum extract; 25 ml of Echinacea purpurea extract; 10 ml of Calendula extract; 15 ml of Licorice extract; and 20 ml of Hypericum extract.
A
The extracts were sourced from MediHerb Pty Ltd of 124 McEvoy Street, Warwick, Queensland 4370, Australia.
MediHerb combined the extracts to form the herbal composition. The herbal composition was prepared using a preferred extraction and composition technique (i.e. cold percolation technique).
The participants in the treatment group were required to take 8ml of the oral herbal formulation, twice daily, with food.
Each participant in the treatment group was also asked to fill in a compliance booklet, with a tick for each dose taken. This data was used to measure the degree of compliance by the participant.
At the end of the l2-week treatment period, the participants in the treatment group, as with the control group, were re-photographed.
Participant withdrawals
By the end of the 12-week treatment period, there were two withdrawals from the treatment group: one woman became pregnant and the other was non-compliant. Therefore the relevant data for these two participants were not collected and are not included in the results. Ome participant withdrew from the control group.
Results
The results were measured by a visual comparison of the photographs before and after treatment.
Four categories were ldentified: ° No Change - there was no apparent changes in the warts (no patient hzd an increass in wart numbers or size); ® Partially Cleared - up to 50% of the warts had been reduced or cleared; . Almost Cleared - more than 50% of the warts had been reduced or cleared; and
J Totally Cleared - all sign of warts had disappeared.
The results were as follows:
No Change Partially |Almost Totally Total
Cleared Cleared Cleaxed Completed
Study treatment |s |e Ja ls la contwor__ Jas [1 Jo Jo fa
It is to be noted that the one participant in the control group who had any sign of change had been given a medical procedure which helped his body’s ability to function better, which may have resulted in the spontaneous disappearance of most of his warts.
Adverse Reactions
No adverse reactions or effects were reported.
Statistical Significance of the Results
There was strong evidence of a difference in wart change between the two groups.
Claims (24)
1. A herbal composition comprising extracts from: Thuja; Buplsurum; Echinacea; Calendula; Licorice; and Hypericum.
2. A herbal composition according to claim 1, wherein the herbal composition comprises from about 0.9% to about 55% of Thuja extract. 1S
3. A herbal composition according to claim 1 or claim 2, wherein the herbal composition comprises from about 0.9% to about 72% of Bupleurum extract.
4. A herbal composition according to any one of the preceding claims, wherein the herbal composition comprises from about 0.9% to about 55% of Echinacea extract.
5. The herbal composition according to any one of the preceding claims, wherein the herbal composition comprises from about 0.9% to about 36% of Calendula extract.
6. The herbal composition according to any one of the preceding claims, wherein the herbal composition comprises from about 0.9% to about 36% of Licorice extract.
7. The herbal composition according to any one of the preceding claims, wherein the herbal composition comprises from about 1.5% to about 55% of Hypericum extract.
8. A herbal composition according to any one of the preceding claims, wherein the herbal composition comprises about 18% of Thuja extract.
9. A herbal composition according to any ons of the preceding claims, wherein the herbal composition comprises about 18% of Bupleurum extract.
10. A herbal composition according to any one of the preceding claims, wherein the herbal composition comprises about 23% of Echinacea extract.
11. A herbal composition according to any one of the preceding claims, wherein the herbal composition comprises about 9% of Calandula extract.
12. A herbal composition according to any one of the preceding claims, wherein the herbal composition comprises about 14% of Licorice extract. :
13. A herbal composition according to any one of the preceding claims, wherein the herbal composition comprises about 18% of Hypericum extract. '
14. A herbal composition according to any one of the preceding claims, wherein the herbal composition further comprises extracts of one or more of Manuka, Lycium, Burdock, Cats Claw, Poke root, Ginger, Thyme, Barberry, Golden Seal and Rehmannia, Schisandra, and St Mary's Thistle.
15. A herbal composition according to claim 14, wherein the herbal composition comprises from about 0.1% to about 30% of extracts of one or more of Manuka, Lycium,
Burdock, Cats Claw, Poke root, Ginger, Thyme, Barbarry, Golden Seal and Rehmannia, Schisandra, and 8t Mary's Thistla.
16. A herbal composition according to claim 15, wherein the herbal composition comprises from about 0.1% to about 10% of extracts of one or more of Manuka, Lycium, Burdock, Cats Claw, Poke root, Ginger, Thyme, Barberry, Golden Seal and Rehmannia, Schisandra, and Bt Mary’s Thistle.
17. A herbal composition according to any one of the preceding claims, wherein the extract is in the form of a tincture, a fluid extract or a solid extract, or a mixture thereof.
18. A herbal composition according to claim 17, wherein the extract is in the form of a tincture.
19. A herbal composition according to claim 18, wherein the tincture is formed from water-based infusions and decoctions.
20. A herbal composition according to any one of the preceding claims, wherein the base for the extract is an acetract to form a vinegar extract, a glycetract to form a glycerine extract, a mel to form a honey extract, an oxymel to form a honey and vinegar extract, or a syrup to form a sugar extract.
21. A herbal formulation comprising a herbal composition according to any one of claims 1 to 20 together with one or more carriers.
22. A herbal formulation according to claim 21, wherein the herbal formulation is in the form of an oral formulation.
23. A herbal formulation according to claim 22, wherein the oral formulation is a solution. S
24. A herbal formulation according to claim 21, wherein the herbal formulation is in the form of a topical formulation.
25. A herbal formulation according to claim 24, wherein the topical formulation is a cream.
26. A method of alleviating, treating and/or preventing symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection which comprises administering a therapeutically effective amount of the herbal composition according to any one of claims 1 to 20 or a herbal formulation according to any one of claims 21 to 25 to a subject in need thereof.
27. A method according to claim 26, wherein the viral infection is one or more of the Herpes Simplex Virus (HSV), the Epstein-Barr Virus (EBV), the Cytomegalo Virus (CMV), the Human Papilloma Virus (HPV), or the Coxsackie B virus.
28. A method according to claim 26 or claim 27, wherein the subject is an animal, mammal or human.
29. A method according to any one of claims 26 to 28, wherein the herbal composition or herbal formulation is in tha form of an oral formulation.
30. A method according to claim 29, wherein from about lml to about 50ml of the oral formulation is administered at least once daily.
31. A method according to claim 30, wherein from about 6ml to about 10ml of the oral formulation is administered at least twice daily.
32. A method according to claim 31, wherein about 8ml of the oral formulation is administered at least twice daily.
33. A method according to any one of claims 26 to 32, wherein the herbal composition is administered in the form of an oral formulation and as a topical formulation.
34. Use of the herbal composition according to any one of claims 1 to 20 or a herbal formulation according to any one of claims 21 to 25 for the manufacture of a medicament to alleviate, treat and/or prevent symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
35. Use of the herbal composition according to any one of claims 1 to 20 or a herbal formulation according to any one of claims 21 to 25 to alleviate, treat and/or prevent symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
36. A herbal composition according to any one of claims 1 to 20 or a herbal formulation according to any one of claims 21 to 25 for use in alleviating, treating and/or preventing symptoms of skin lesions, sores, cold sores, blisters, warts, lumps, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
317. An agent comprising a herbal composition according to any one of claims 1 to 20 or a herbal formulation according to any one of claims 21 to 25 for alleviating, treating and/or preventing symptoms of skin lesions, sores, cold soras, blisters, warts, lumpe, bumps, pimples, rashes and ulcers associated with or caused by a viral infection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200609458A ZA200609458B (en) | 2004-04-14 | 2004-04-14 | Herbal composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200609458A ZA200609458B (en) | 2004-04-14 | 2004-04-14 | Herbal composition |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200609458B true ZA200609458B (en) | 2008-01-30 |
Family
ID=40635437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200609458A ZA200609458B (en) | 2004-04-14 | 2004-04-14 | Herbal composition |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200609458B (en) |
-
2004
- 2004-04-14 ZA ZA200609458A patent/ZA200609458B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU749922B2 (en) | A medicament for treating recurrent ulcer of mouth and Behcet's syndrome | |
DE19953829C2 (en) | Nasal spray (drops) for the treatment of fever, cold and its manufacture | |
CN103356443A (en) | Toothpaste | |
CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
CN104257704A (en) | Novel application of eurycoma longifolia extracts | |
US20070212432A1 (en) | Herbal Composition | |
US20080138446A1 (en) | Herbal Composition | |
CN114470042B (en) | Composition for preventing and treating liver injury of animals as well as preparation method and application thereof | |
CN110664858A (en) | Artemisia annua extract composition for skin, product and application thereof | |
CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
CN100486636C (en) | Paste for treating dental hyperesthesia and its preparing method | |
CN1050054C (en) | Fugong granule for postpartum disease | |
ZA200609458B (en) | Herbal composition | |
CN105031284A (en) | Oral medicament for treatment of oral leukoplakia | |
RU2303993C1 (en) | Treatment and prophylaxis means applicable for treating young agricultural animals and method for preventing and treating calves for gastrointestinal tract diseases | |
Campbell | Pharmacy in ancient Egypt | |
CN101371861A (en) | High-efficient antiviral medicament composition in chickweed as well as preparation method and use thereof | |
CN102908508B (en) | Medicinal composition for treating seborrheic alopecia and preparation method thereof | |
CN1116887C (en) | Defervescent and its preparing process | |
KR20070049604A (en) | Herbal composition | |
CN1289122C (en) | Medicinal composition for treating psoriasis and preparation method thereof | |
CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
CN102949678B (en) | Traditional Chinese medicine for treating recurrent aphthae and preparation method and application thereof | |
CN115154571A (en) | Antibacterial composition and application thereof | |
Zelenková et al. | Preparations containing Glycyrrhizic Acid in dermatological practice |